CVS Related Analyst Ratings
-
Cardinal Health (CAH) Needs CVS Renewal After Walgreen Loss - Analyst
-
Goldman Sachs Downgrades CVS Caremark (CVS) to Neutral, Few Catalysts
-
Jefferies Boosts Numbers on CVS (CVS) Post Analyst Day
-
CVS (CVS) Taking Walgreen (WAG) Share - Analyst
-
Macquarie Upgrades CVS Caremark (CVS) to Outperform
-
Jefferies Lifts Numbers on CVS Caremark (CVS) on Strong Q3
-
Jefferies Cuts PT on Green Dot (GDOT), Sees Another Large Client May Move to AmEx (AXP)
-
LabCorp (LH) Could See a Hit from Aetna/Coventry Health Deal
-
CVS Caremark (CVS) Will Come Out A Winner in Aetna/Coventry Deal
-
Cantor Fitzgerald Starts CVS Caremark (CVS) at Buy; Riding the Generic Wave
-
BMO Capital Upgrades CVS Caremark (CVS) to Outperform
-
JMP Resumes PBM Providers: CVS, MCK, ESRX at Outperform, CTRX at Market Perform
-
JMP Securities Resumes CVS Caremark (CVS) at Market Outperform
-
ISI Group Starts CVS Caremark (CVS) at Overweight
-
Goldman Sachs Resumes Coverage on SXC Health Solutions (SXCI) at Buy; Strong Growth Beyond Integration
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); OraQuick HIV-OTC Test in 30,000 Locations
-
Barclays Maintains an 'Overweight' on CVS Caremark (CVS); Positive on Shares After Mee ing
-
UBS Maintains a 'Buy' on Cardinal Health (CAH); Color on Safeway Contract
-
UBS Raises Numbers on CVS Caremark (CVS); Comments From Conference Call
-
Jefferies Boosts Price Target on CVS Caremark (CVS) After Q1 Results
-
UBS on Healthcare Distribution - PBMs: Implications from SXCI/CHSI Deal
-
BMO Capital Downgrades CVS Caremark (CVS) to Market Perform
-
Jefferies Maintains a 'Buy' on CVS Caremark (CVS); A Superior Model
-
UBS Maintains a 'Buy' on CVS Caremark (CVS); Raising FY12/13 EPS Estimates
-
Macquarie Downgrades CVS Caremark (CVS) to Neutral
-
Q4 Preview: CVS (CVS) Quarter Should Be Telegraphed But Investors Will Want Details
-
Citi Adds CVS (CVS) to 'Top Picks Live' List Ahead of Q4 Results
-
UBS Maintains a 'Buy' on Walgreen (WAG); January Comps Will Represent First Month Without ESRX
-
UBS Maintains a 'Neutral' on CVS Caremark (CVS); Raising ‘13 EPS for Generics/PBM Mojo
-
Macquarie Starts CVS Caremark (CVS) at Outperform
-
Barclays 2012 Top Picks: Becoming Somewhat More Optimistic - Signs of Progress, Growth and Soft Landings
-
Goldman Sachs Lifts Price Target On CVS Caremark (CVS)
-
RBC Capital Upgrades CVS Caremark (CVS) to Outperform
-
UBS Maintains a 'Buy' on CVS Caremark (CVS); Post-Call: Plenty of Positive Datapoints
-
Jefferies Raises Price Target on CVS Caremark (CVS), Sees Upside Potential
-
Morgan Stanley Upgrades CVS Caremark (CVS) to Overweight
-
Barclays Maintains an 'Overweight' on CVS Caremark (CVS); 3Q11 Earnings Preview
-
Citi Says Buy CVS (CVS) Ahead of Q3 Results as Walgreen/Express Scripts Talks Ongoing
-
Mizuho Securities Starts CVS Caremark (CVS) at Buy
-
Jefferies Cuts Price Target on Walgreen (WAG), Encourges a Settlement with Express Scripts (ESRX)
-
Deutsche Bank Starts CVS Caremark (CVS) at Hold, Long-Term Looks Strong
-
UBS Maintains a 'Neutral' on Rite-Aid (RAD); Raising PT on Business Momentum
-
Q2 Preview: CVS (CVS) Looking to PBM to Continue Strong Results
-
CVS (CVS) Shares Positive as JPMorgan Adds to 'Focus List'
-
William Blair Upgrades CVS Caremark (CVS) to Outperform
-
Dahlman Rose Starts CVS Caremark (CVS) at Buy, Strong Business Model
-
Dahlman Rose Starts 13 Retail Stocks: WMT, TGT, CVS, KR at Buy, COST, FDO, WFM at Hold
-
Barclays Maintains an 'Equalweight' on Walgreen (WAG); Drawing a Line in the Sand
-
UPDATE - UBS Initiates Coverage on Rite Aid (RAD) with a Neutral; Between A Rock and a Hard Place
-
FBR Capital Maintains an 'Outperform' on Medco Health (MHS); Removes as Top Pick
Back to CVS Stock Lookup
